RxDoctor Payments Data

Khader Mustafa

Rheumatology · Sylvania, OHNPI 1881078533

Payments from drug & device makers

$4,064in general payments, 2019–2025

Across 216 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$902
  • Johnson & Johnson$282
  • Novartis$244
  • UCB, Inc.$214
  • E.r. Squibb & Sons, L.L.C.$210
  • plus $900 from 14 others

What the payments were for

  • Food & beverage$4,00999%
  • Education$551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,064 in reported general payments places this provider in the 60th percentile of 255 rheumatology providers in Ohio.

See all rheumatology providers in Ohio

Medicare billing

Part B allowed, 2024
$48,745
Medicare patients
198
Services billed
691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab51$342,073
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5024$171,607
Cosentyx Sensoready (2 Pens)Secukinumab12$88,874
XeljanzTofacitinib Citrate11$65,185
ActemraTocilizumab12$35,398
Duloxetine Hcl186$11,949
Hydroxychloroquine Sulfate213$9,534
Mycophenolate Mofetil59$7,822
Amitriptyline Hcl393$5,148
Pregabalin95$4,765
Tizanidine Hcl474$3,645
Celecoxib106$3,534
MethotrexateMethotrexate Sodium151$3,422
Prednisone498$2,955
Gabapentin187$2,183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$138$65,18511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 255 rheumatology providers in Ohio.

Other rheumatology in Sylvania

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →